重组复合高效干扰素抗人乳腺癌细胞的体外实验研究

目的 了解重组复合高效干扰素(rSIFN-co)在体外抗乳腺癌细胞的作用,以及与抗肿瘤药物合用的协同抗肿瘤作用,并初步探讨其可能的作用机理.方法 采用MTT比色法和流式细胞仅技术,检测rSIFN-co、干扰素(干复津)、抗肿瘤药物(盐酸表柔比星),以及联合用药对人乳腺癌MCF-7细胞及人乳腺癌阿霉素耐药MCF-7/ADR细胞增殖、凋亡的影响,采用免疫组化SABC法检测经过各药物处理的MCF-7细胞及MCF-7/ADR细胞中P53、Bcl-2、CerbB-2蛋白的表达.结果 rSIFN-co对MCF-7细胞及MCF-7/ADR细胞均具有增殖抑制、促进凋亡作用,作用强于干复津,且有剂量依赖性及时间依赖性倾向;rSIFN-co与盐酸表柔比星联用具有协同增效的作用;rSIFN-co可下调MCF-7细胞及MCF-7/ADR细胞P53、CerbB-2蛋白及上调Bcl-2蛋白的表达水平.结论 rSIFN-co诱导MCF-7细胞及MCF-7/ADR细胞凋亡、抑制其增殖作用可能与下调肿瘤细胞P53、CerbB-2蛋白及上调Bcl-2蛋白的表达水平有关.

Effect of Recombinant Super-compound Interferon(rSIFN-co)on Human Breast Cancer Cells in vitro

Objective To study the anti-cancer activities of recombinant super-compound interferon(rSIFN-co)against human breast cancer cells,its cooperative anti-tumor effect with chemotherapy and the possible mechanism of these effects.Methods The rSIFN-co,infergen,epirubicin were applied separately or combined in cultured human breast cancer cells MCF-7 and adriamycin-resistant strains of MCF-7/ADR cells.MTT assays and flow cytometry were applied to determine the growth inhibition and cell apoptosis index(AI)of MCF-7 and MCF-7/ADR after different treatment.Immunohistochemical was used to detect the expression of P53,Bcl-2,CerbB-2 in treated MCF-7 and MCF-7/ADR cells.Results The rSIFN-co demonstrated a efficiency of inhibiting the cell proliferation,induce apoptosis of both MCF-7 cells and MCF-7/ADR cells,which was stronger than that of infergen in the same concentration;rSIFN-co combined with epirubicin has a synergistic action in inhibiting cell proliferation,inducing apoptosis of both type of breast cancer cells;rSIFN-co can also decrease the expression level of P53 and CerbB-2,increase the expression of Bcl-2 in both cell lines.Conclusion In vitro conditions,rSIFN-co can inhibit cell growth of human breast cancer cell MCF-7 and MCF-7/ADR,which may attribute to influence the proliferationassociated factor expression,and induce apoptosis of cancer cells.